CANNABIS Derivative (Sativex®)
Clinical Indication
Multiple sclerosis
Date of classification
June 2015
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.